Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2013 Aug 29;122(9):1610-20. doi: 10.1182/blood-2013-01-481457. Epub 2013 Jul 1.

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.

Author information

1
Novartis Institutes for Biomedical Research, Emeryville, CA 94508, USA.

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy. Despite recent treatment advances, it remains incurable. Here, we report that Pim2 kinase expression is highly elevated in MM cells and demonstrate that it is required for MM cell proliferation. Functional interference of Pim2 activity either by short hairpin RNAs or by a potent and selective small-molecule inhibitor leads to significant inhibition of MM cell proliferation. Pim inhibition results in a significant decrease of mammalian target of rapamycin C1 (mTOR-C1) activity, which is critical for cell proliferation. We identify TSC2, a negative regulator of mTOR-C1, as a novel Pim2 substrate and show that Pim2 directly phosphorylates TSC2 on Ser-1798 and relieves the suppression of TSC2 on mTOR-C1. These findings support Pim2 as a promising therapeutic target for MM and define a novel Pim2-TSC2-mTOR-C1 pathway that drives MM proliferation.

PMID:
23818547
PMCID:
PMC3953014
DOI:
10.1182/blood-2013-01-481457
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center